New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback